GOLDSTEIN JOSEPH L 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Apr 1, 2022
Insider Transaction Report
Form 4
GOLDSTEIN JOSEPH L
Director
Transactions
- Exercise/Conversion
Common Stock
2022-03-30$374.12/sh+2,431$909,486→ 8,513 total - Sale
Common Stock
2022-03-30$700.00/sh−2,431$1,701,700→ 6,082 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2022-03-30−2,431→ 0 totalExercise: $374.12Exp: 2030-01-02→ Common Stock (2,431 underlying)
Footnotes (2)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- [F2]On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.